Literature DB >> 17237608

In vitro infection of immortalized primary hepatocytes by HCV genotype 4a and inhibition of virus replication by cyclosporin.

Mohamed A El-Farrash1, Hussein H Aly, Koichi Watashi, Makoto Hijikata, Hiroto Egawa, Kunitada Shimotohno.   

Abstract

Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma worldwide. We previously reported that cyclosporin A (CsA) inhibits HCV-1b replication. However, its inhibition of JFH-1 (HCV-2a) was much less. Since HCV genotype clearly affects the in vitro and in vivo response to anti-viral therapy, we wished to examine the effect of CsA and its non-immunosuppressive derivative NIM811 on HCV genotype 4a replication. We first established an in vitro system supporting HCV-4a infection and replication using immortalized human hepatocytes, HuS-E7/DN24 (HuS) cells, and these cells were infected with sera obtained from Egyptian patients with chronic HCV-4a infection. HuS cells supported more robust HCV-4a replication than both HuH-7.5 and PH5CH8 cells, and HCV-4a infection and replication were completely inhibited by 3 mug/ml CsA and 0.5 mug/ml NIM811. Thus, HuS cells are a good model system supporting the infection and high-level replication of HCV-4a, and both CsA and NIM811 effectively inhibit HCV-4a replication in this system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17237608     DOI: 10.1111/j.1348-0421.2007.tb03883.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  5 in total

1.  Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: an in vitro proof-of-concept.

Authors:  C Leboeuf; J Roser-Schilder; M Lambotin; S Durand; T Wu; C Fauvelle; B Su; E Bôle-Richard; M Deschamps; C Ferrand; P Tiberghien; P Pessaux; T F Baumert; E Robinet
Journal:  Gene Ther       Date:  2014-11-13       Impact factor: 5.250

2.  A locking mechanism regulates RNA synthesis and host protein interaction by the hepatitis C virus polymerase.

Authors:  Sreedhar Chinnaswamy; Ian Yarbrough; Satheesh Palaninathan; C T Ranjith Kumar; Vinodhini Vijayaraghavan; Borries Demeler; Stanley M Lemon; James C Sacchettini; C Cheng Kao
Journal:  J Biol Chem       Date:  2008-04-28       Impact factor: 5.157

3.  Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infection.

Authors:  Mahmoud Aboelneen Khattab; Mohammed Eslam; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2010-12-01       Impact factor: 0.660

4.  Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP).

Authors:  Koichi Watashi; Ann Sluder; Takuji Daito; Satoko Matsunaga; Akihide Ryo; Shushi Nagamori; Masashi Iwamoto; Syo Nakajima; Senko Tsukuda; Katyna Borroto-Esoda; Masaya Sugiyama; Yasuhito Tanaka; Yoshikatsu Kanai; Hiroyuki Kusuhara; Masashi Mizokami; Takaji Wakita
Journal:  Hepatology       Date:  2014-04-01       Impact factor: 17.425

5.  Hepatitis c virus genotype 4 replication in the hepatocellular carcinoma cell line HepG2/C3A.

Authors:  Medhat K Shier; Mohammad S El-Wetidy; Hebatallah H Ali; Mohammad M Al-Qattan
Journal:  Saudi J Gastroenterol       Date:  2016 May-Jun       Impact factor: 2.485

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.